Basilea Pharmaceutica AG Stock
Stocks
BSLN
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Cboe Europe
23:20:00 04/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 64.75 CHF | -1.30% |
|
-0.16% | +17.73% |
| 08-19 | Basilea Pharmaceutica Ag Raises Earnings Guidance for the Full Year 2026 | CI |
| 08-18 | Swiss Market Index Closes Higher; Huber+Suhner Shares Drop | MT |
| Market Cap | 815M 1.01B 868M 745M 1.39B 95.38B 1.4B 9.64B 3.75B 48.74B 3.79B 3.71B 157B | P/E 2026 * |
19.3x | P/E 2027 * | 19.8x |
|---|---|---|---|---|---|
| Enterprise Value | 665M 823M 708M 608M 1.13B 77.81B 1.14B 7.86B 3.06B 39.76B 3.09B 3.02B 128B | EV / Sales 2026 * |
2.55x | EV / Sales 2027 * | 2.22x |
| Free-Float |
91.84% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| BSLN | Delayed | |
CBOE
| 0QNA | Real-time | |
|
Deutsche Boerse AG
| PK5 | Delayed | |
|
London S.E.
| 0QNA | Delayed | |
|
OTC Markets
| BPMUF | Delayed | |
|
Tradegate
| PK5 | Real-time | |
|
Börse Stuttgart
| PK5 | Delayed | |
|
Boerse Muenchen
| PK5 | Real-time |
Last Transcript : Basilea Pharmaceutica AG
| 1 day | -1.30% | ||
| 1 week | -0.16% | ||
| Current month | +1.42% | ||
| 1 month | +27.52% | ||
| 3 months | +29.19% | ||
| 6 months | +19.70% | ||
| Current year | +17.73% |
| 1 week | 62.6 |  | 67.4 |
| 1 month | 50.4 | | 67.4 |
| Current year | 47.8 | | 67.4 |
| 1 year | 44.7 | | 67.4 |
| 3 years | 32 | | 67.4 |
| 5 years | 29.55 | | 67.4 |
| 10 years | 29.28 | | 95.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 19/04/2018 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 10/04/2019 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/05/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 29/11/2011 |
| Chairman | 71 | 09/04/2013 | |
Nicole Onetto
BRD | Director/Board Member | 73 | 27/04/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 29/5/26 | Sell | -400 | 0.0030% | |||
| 13/5/26 | Sell | -1,043 | 0.0078% | |||
| 4/5/26 | Sell | 400 | 0.0030% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.30% | -0.16% | +36.15% | +35.86% | 1.01B | |
| -2.68% | -2.40% | -1.45% | +15.04% | 50.35B | |
| -0.93% | +0.11% | +434.30% | +517.72% | 45.2B | |
| -1.58% | +1.72% | +44.63% | +20.53% | 44.71B | |
| -0.81% | -2.14% | +12.60% | +75.20% | 41.24B | |
| +0.53% | -1.67% | +15.16% | +49.88% | 33.08B | |
| -1.08% | +7.96% | - | - | 17.81B | |
| +0.04% | -1.29% | +22.93% | +123.66% | 16.56B | |
| -1.01% | +0.50% | +15.83% | +27.98% | 14.82B | |
| -1.15% | -0.84% | +78.09% | +41.50% | 14B | |
| Average | -1.04% | +0.04% | +73.14% | +100.82% | 27.88B | |
| Weighted average by Cap. | -1.17% | -0.46% | +93.18% | +126.09% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 261M 323M 278M 238M 445M 30.52B 449M 3.08B 1.2B 15.59B 1.21B 1.19B 50.22B | 271M 335M 288M 248M 462M 31.67B 466M 3.2B 1.25B 16.19B 1.26B 1.23B 52.13B |
| Net income | 53.56M 66.33M 57.07M 49M 91.46M 6.27B 92.18M 634M 247M 3.2B 249M 244M 10.32B | 44.43M 55.03M 47.35M 40.65M 75.87M 5.2B 76.47M 526M 205M 2.66B 207M 202M 8.56B |
| Net Debt | -150M -186M -160M -137M -256M -17.57B -258M -1.78B -691M -8.98B -698M -683M -28.92B | -214M -265M -228M -196M -365M -25.02B -368M -2.53B -984M -12.79B -994M -972M -41.18B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/09/26 | CHF 64.40 | -1.83% | 17,110 |
| 03/09/26 | CHF 65.60 | -0.15% | 42,090 |
| 02/09/26 | CHF 65.70 | +3.79% | 108,913 |
| 01/09/26 | CHF 63.30 | -0.31% | 39,067 |
| 31/08/26 | CHF 63.50 | -1.55% | 45,150 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BSLN Stock
Select your edition
All financial news and data tailored to specific country editions
